Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

doi:10.3748/wjg.v20.i32.11384

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 32

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8997)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

624

WORD

339

HTML

5126

Figures (1-3)

189

Tables (1-6)

190

Sum=6468

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1379

Download

1150

Sum=2529

Aug 28, 2014 (publication date) through Sep 1, 2024

Times Cited of This Article

Times Cited (52)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Aug 28, 2014; 20(32): 11384-11393
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11384

Full Size Figure Download Figure

Figure 3 Subgroup analysis of 3-year disease-free survival probability for high-risk subgroups in Groups A, B and C.

Citation: Liu CJ, Chang J, Lee PH, Lin DY, Wu CC, Jeng LB, Lin YJ, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Yang MD, Yu MC, Hu RH, Peng CY, Lai KL, Chang SSC, Chen PJ. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(32): 11384-11393
URL: https://www.wjgnet.com/1007-9327/full/v20/i32/11384.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i32.11384